trans-2,3-enoyl-CoA reductaseGenealiases: GPSN2 · MRT14 · SC2 · TER
Q-omics provides the consensus-scored TECR profile across patient tissues and cancer cell-line models. TECR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TECR is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TECR protein abundance shows 36,716 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, COAD, and GBM as cancer lineages where TECR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TECR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TECR survival associations across molecular data types. TECR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TECR RNA expression–survival associations across cancer types. High TECR expression shows unfavorable associations in BLCA, OV and LIHC, but favorable associations in LUSC, THYM and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TECR RNA expression.
This table summarizes TECR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 13. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TECR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TECR shows lower tumor expression in HNSC and THCA and higher tumor expression in COAD, LIHC, LUSC and BLCA. The COAD box plot shows higher TECR RNA expression in tumor versus normal tissue (log2 FC = +0.646, t-test p < 0.001).
This table shows molecular features associated with TECR in patient tissues and cancer cell lines. In patient samples, TECR shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TECR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
